272 related articles for article (PubMed ID: 35010811)
1. Hypothesizing in the Face of the Opioid Crisis Coupling Genetic Addiction Risk Severity (GARS) Testing with Electrotherapeutic Nonopioid Modalities Such as H-Wave Could Attenuate Both Pain and Hedonic Addictive Behaviors.
Gupta A; Bowirrat A; Gomez LL; Baron D; Elman I; Giordano J; Jalali R; Badgaiyan RD; Modestino EJ; Gold MS; Braverman ER; Bajaj A; Blum K
Int J Environ Res Public Health; 2022 Jan; 19(1):. PubMed ID: 35010811
[TBL] [Abstract][Full Text] [Related]
2. High Genetic Addiction Risk Score (GARS) in Chronically Prescribed Severe Chronic Opioid Probands Attending Multi-pain Clinics: an Open Clinical Pilot Trial.
Moran M; Blum K; Ponce JV; Lott L; Gondré-Lewis MC; Badgaiyan S; Brewer R; Downs BW; Fynman P; Weingarten A; Cadet JL; Smith DE; Baron D; Thanos PK; Modestino EJ; Badgaiyan RD; Elman I; Gold MS
Mol Neurobiol; 2021 Jul; 58(7):3335-3346. PubMed ID: 33683627
[TBL] [Abstract][Full Text] [Related]
3. Insurance Companies Fighting the Peer Review Empire without any Validity: the Case for Addiction and Pain Modalities in the face of an American Drug Epidemic.
Blum K; Jacobs W; Modestino EJ; DiNubile N; Baron D; McLaughlin T; Siwicki D; Elman I; Moran M; Braverman ER; Thanos PK; Badgaiyan RD
SEJ Surg Pain; 2018 Oct; 1(1):1-11. PubMed ID: 29911684
[TBL] [Abstract][Full Text] [Related]
4. DNA Directed Pro-Dopamine Regulation Coupling Subluxation Repair, H-Wave
Bajaj A; Blum K; Bowirrat A; Gupta A; Baron D; Fugel D; Nicholson A; Fitch T; Downs BW; Bagchi D; Dennen CA; Badgaiyan RD
J Pers Med; 2022 Aug; 12(9):. PubMed ID: 36143203
[TBL] [Abstract][Full Text] [Related]
5. Beyond Mor: Can Induction of Dopamine Homeostasis Along with Electrotherapy Attenuate the Opioid Crisis?
Blum K; Bowirrat A; Braverman ER; Dennen C; Zeine F; Jafari N; Sunder K; Thanos PK; Baron D; Barh D; Gupta A; Bagchi D; Gold MS; Badgaiyan RD
Clin Exp Psychol; 2023 Mar; 9(2):1-3. PubMed ID: 37363693
[TBL] [Abstract][Full Text] [Related]
6. The Benefits of Genetic Addiction Risk Score (GARS
Blum K; Modestino EJ; Gondre-Lewis M; Chapman EJ; Neary J; Siwicki D; Baron D; Hauser M; Smith DE; Roy AK; Thanos PK; Steinberg B; McLaughlin T; Fried L; Barh D; Dunston GA; Badgaiyan RD
Int J Genom Data Min; 2018; 2018(1):. PubMed ID: 30198022
[TBL] [Abstract][Full Text] [Related]
7. Genetic addiction risk score (GARS) ™, a predictor of vulnerability to opioid dependence.
Blum K; Chen ALC; Thanos PK; Febo M; Demetrovics Z; Dushaj K; Kovoor A; Baron D; Smith DE; Roy AK; Fried L; Chen TJH; Chapman E; Modestino EJ; Steinberg B; Badgaiyan RD
Front Biosci (Elite Ed); 2018 Jan; 10(1):175-196. PubMed ID: 28930612
[TBL] [Abstract][Full Text] [Related]
8. Reward Deficiency Syndrome (RDS): A Cytoarchitectural Common Neurobiological Trait of All Addictions.
Blum K; Bowirrat A; Braverman ER; Baron D; Cadet JL; Kazmi S; Elman I; Thanos PK; Badgaiyan RD; Downs WB; Bagchi D; Llanos-Gomez L; Gold MS
Int J Environ Res Public Health; 2021 Nov; 18(21):. PubMed ID: 34770047
[TBL] [Abstract][Full Text] [Related]
9. Biotechnical development of genetic addiction risk score (GARS) and selective evidence for inclusion of polymorphic allelic risk in substance use disorder (SUD).
Blum K; Bowirrat A; Baron D; Lott L; Ponce JV; Brewer R; Siwicki D; Boyett B; Gondre-Lewis MC; Smith DE; Panayotis K T; Badgaiyan S; Hauser M; Fried L; A R; Downs BW; Badgaiyan RD
J Syst Integr Neurosci; 2020 Aug; 6(2):. PubMed ID: 33614164
[TBL] [Abstract][Full Text] [Related]
10. The Opioid Crisis and the Future of Addiction and Pain Therapeutics.
Coussens NP; Sittampalam GS; Jonson SG; Hall MD; Gorby HE; Tamiz AP; McManus OB; Felder CC; Rasmussen K
J Pharmacol Exp Ther; 2019 Nov; 371(2):396-408. PubMed ID: 31481516
[TBL] [Abstract][Full Text] [Related]
11. Measuring opioid dependence in chronic pain patients: A comparison between addiction clinic and pain clinic patient populations.
McDonough M; Johnson JL; White JM; Buisman-Pijlman FTA
J Opioid Manag; 2019; 15(4):285-293. PubMed ID: 31637681
[TBL] [Abstract][Full Text] [Related]
12. The role of neurologists in tackling the opioid epidemic.
Volkow ND; Koroshetz WJ
Nat Rev Neurol; 2019 May; 15(5):301-305. PubMed ID: 30792513
[TBL] [Abstract][Full Text] [Related]
13. Pain Control in the Presence of Drug Addiction.
Vadivelu N; Lumermann L; Zhu R; Kodumudi G; Elhassan AO; Kaye AD
Curr Pain Headache Rep; 2016 May; 20(5):35. PubMed ID: 27068665
[TBL] [Abstract][Full Text] [Related]
14. The downward spiral of chronic pain, prescription opioid misuse, and addiction: cognitive, affective, and neuropsychopharmacologic pathways.
Garland EL; Froeliger B; Zeidan F; Partin K; Howard MO
Neurosci Biobehav Rev; 2013 Dec; 37(10 Pt 2):2597-607. PubMed ID: 23988582
[TBL] [Abstract][Full Text] [Related]
15. Responsible, Safe, and Effective Prescription of Opioids for Chronic Non-Cancer Pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines.
Manchikanti L; Kaye AM; Knezevic NN; McAnally H; Slavin K; Trescot AM; Blank S; Pampati V; Abdi S; Grider JS; Kaye AD; Manchikanti KN; Cordner H; Gharibo CG; Harned ME; Albers SL; Atluri S; Aydin SM; Bakshi S; Barkin RL; Benyamin RM; Boswell MV; Buenaventura RM; Calodney AK; Cedeno DL; Datta S; Deer TR; Fellows B; Galan V; Grami V; Hansen H; Helm Ii S; Justiz R; Koyyalagunta D; Malla Y; Navani A; Nouri KH; Pasupuleti R; Sehgal N; Silverman SM; Simopoulos TT; Singh V; Solanki DR; Staats PS; Vallejo R; Wargo BW; Watanabe A; Hirsch JA
Pain Physician; 2017 Feb; 20(2S):S3-S92. PubMed ID: 28226332
[TBL] [Abstract][Full Text] [Related]
16. The Science of Addiction Through the Lens of Opioid Treatment for Chronic Noncancer Pain.
Umberger W; Gaddis L
Pain Manag Nurs; 2020 Feb; 21(1):57-64. PubMed ID: 31606310
[TBL] [Abstract][Full Text] [Related]
17. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2--guidance.
Manchikanti L; Abdi S; Atluri S; Balog CC; Benyamin RM; Boswell MV; Brown KR; Bruel BM; Bryce DA; Burks PA; Burton AW; Calodney AK; Caraway DL; Cash KA; Christo PJ; Damron KS; Datta S; Deer TR; Diwan S; Eriator I; Falco FJ; Fellows B; Geffert S; Gharibo CG; Glaser SE; Grider JS; Hameed H; Hameed M; Hansen H; Harned ME; Hayek SM; Helm S; Hirsch JA; Janata JW; Kaye AD; Kaye AM; Kloth DS; Koyyalagunta D; Lee M; Malla Y; Manchikanti KN; McManus CD; Pampati V; Parr AT; Pasupuleti R; Patel VB; Sehgal N; Silverman SM; Singh V; Smith HS; Snook LT; Solanki DR; Tracy DH; Vallejo R; Wargo BW;
Pain Physician; 2012 Jul; 15(3 Suppl):S67-116. PubMed ID: 22786449
[TBL] [Abstract][Full Text] [Related]
18. The risk for problematic opioid use in chronic pain: What can we learn from studies of pain and reward?
Finan PH; Remeniuk B; Dunn KE
Prog Neuropsychopharmacol Biol Psychiatry; 2018 Dec; 87(Pt B):255-262. PubMed ID: 28778406
[TBL] [Abstract][Full Text] [Related]
19. Prescription Opioid Abuse in Chronic Pain: An Updated Review of Opioid Abuse Predictors and Strategies to Curb Opioid Abuse (Part 2).
Kaye AD; Jones MR; Kaye AM; Ripoll JG; Jones DE; Galan V; Beakley BD; Calixto F; Bolden JL; Urman RD; Manchikanti L
Pain Physician; 2017 Feb; 20(2S):S111-S133. PubMed ID: 28226334
[TBL] [Abstract][Full Text] [Related]
20. Neurological correlates of brain reward circuitry linked to opioid use disorder (OUD): Do homo sapiens acquire or have a reward deficiency syndrome?
Gold MS; Baron D; Bowirrat A; Blum K
J Neurol Sci; 2020 Nov; 418():117137. PubMed ID: 32957037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
